Evidence map›Paper›PMID 38225507›Full record

ArticleJournal of community genetics2024

Advertisement by medical facilities as an opportunity route of APOE genetic testing in Japan: a website analysis.

Kenichiro Sato, Yoshiki Niimi, Ryoko Ihara, Atsushi Iwata, Takeshi Ikeuchi, Takeshi Iwatsubo

Open access · hybridAbstract read
In one paragraph

Article in Journal of community genetics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
3.3field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Kenichiro SatoDepartment of Neuropathology, Graduate School of Medicine, The University of Tokyo, Hongo 7-3-1, Bunkyo-Ku, Tokyo, 113-8655, Japan. kenisatou@m.u-tokyo.ac.jp.
Yoshiki NiimiUnit for Early and Exploratory Clinical Development, The University of Tokyo Hospital, Hongo 7-3-1, Bunkyo-Ku, Tokyo, 113-8655, Japan.
Ryoko IharaDepartment of Neurology, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Sakaecho 35-2, Itabashi-Ku, Tokyo, 173-0015, Japan.
Atsushi IwataDepartment of Neurology, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Sakaecho 35-2, Itabashi-Ku, Tokyo, 173-0015, Japan.
Takeshi IkeuchiDepartment of Molecular Genetics, Brain Research Institute, Niigata University, Asahimachidori 1-757, Chuo-Ku, Niigata, 951-8585, Japan.
Takeshi IwatsuboDepartment of Neuropathology, Graduate School of Medicine, The University of Tokyo, Hongo 7-3-1, Bunkyo-Ku, Tokyo, 113-8655, Japan. iwatsubo@m.u-tokyo.ac.jp.
Tokyo Metropolitan Institute of Gerontology · JPUniversity of Tokyo Hospital · JPNiigata University · JPThe University of Tokyo · JP

Funding

Japan Agency for Medical Research and Development JP21dk0207048Japan Agency for Medical Research and Development JP21dk0207054JSPS KAKENHI 21K20891
6 · The paper itself

Abstract

The APOE-ε4 allele(s) is a strong risk factor for Alzheimer's disease (AD). A significant point of access for this allele testing is through services provided by medical facilities in Japan, which advertise out-of-insurance APOE testing on their websites. There is a concern that website advertisements for APOE testing may influence the ability for individuals to adequately self-determine whether to undergo APOE testing. We conducted a cross-sectional survey on medical facility websites in Japan advertising APOE genetic testing. We predefined desirable features for advertisement descriptions based on legal regulations and guidelines published by relevant professional societies and evaluated each website according to these features. We identified 220 medical facilities that had posted advertisements on their websites for the provision of APOE genetic testing, of which 85% were small clinics. Contact information, details, and costs of testing were described in most of the websites. Meanwhile, features such as "explaining APOE as a risk gene," "notes on interpreting APOE results," or "explaining examination methods" (e.g., blood sampling) were described to a variable degree depending on individual facilities. "Notes on genetic testing" or "referring to genetic counseling" were hardly referred to, and specialists with appropriate expertise were considered to participate in clinical practice in approximately one-third of these facilities providing APOE testing services. These website evaluation results showed moderate to substantial reliability between independent raters. These results suggest that self-determination of pursuing out-of-insurance APOE testing at some medical facilities in Japan may possibly be influenced in an inappropriate manner, at least in its entry route of taking the test.

Indexed as

AdvertisementsAlzheimer’s diseaseAPOEGenetic testingWebsite analysis

Identifiers

PMID38225507
PMCPMC11031550
OpenAlexW4390892868

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.